Mitsubishi Tanabe Pharma GmbH (MTPD) is headquartered in Düsseldorf and is a 100% subsidiary of Mitsubishi Tanabe Pharma Europe Ltd.; it serves as the Marketing Authorization Holder (MAH) for pharmaceuticals in Europe. The company is registered in the Düsseldorf commercial register (HR B 47940) and is classified in the annual financial statements as a medium-sized corporation (§ 267 HGB); it maintains branches in Vienna and Zurich. In fiscal year 2023/24 MTPD reported a gross result of €13,483,885.19 and net profit of €1,221,939.36, with the oral formulation of Radicava® contributing substantially to revenue growth. On 16 July 2024 the company sold the license to distribute Argatra® in an asset deal.
Herstellung, Kauf, Verkauf, Export, Import, Lagerung, Marketing und Vertrieb von pharmazeutischen Produkten sowie Roh- und Hilfsstoffen für pharmazeutische Produkte.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 47940 (as of 2 November 2026)
| Name | Type | City |
|---|---|---|
| Martin Davies | Geschäftsführer(in) | Corwen |
| Kengo Isshiki | Geschäftsführer(in) | London |
| Toshifumi Tada | Geschäftsführer(in) | Tokio |
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 47940 (as of 2 November 2026)
| Date | Event Type | Event |
|---|---|---|
| 22.12.2025 | Registered Seat Change | Tanabe Pharma GmbH Zweigniederlassung |
| 22.12.2025 | Business Address Change | Kolonitzgasse 2A/DG, 1030 Wien/Österreich |
| 02.12.2025 | Company Name Change | Tanabe Pharma GmbH |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 07.05.2003 | Share Capital Set | — | 25.000 € |
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 47940 (as of 2 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | Rohergebnis€11.4M2 | €1,843,624 | €19,357,929 | — |
| 2024 | Rohergebnis€13.5M2 | €1,221,939 | €17,267,063 | — |
| 2023 | Rohergebnis€12.8M2 | €735,598 | €15,154,478 | — |
| 2022 | Rohergebnis€17.6M2 | €1,053,373 | €20,217,677 | — |
| 2021 | Rohergebnis€15.3M2 | €984,523 | €15,337,196 | — |
| 2020 | Rohergebnis€9.6M2 | €940,919 | €12,576,978 | — |
| 2019 | Rohergebnis€10M2 | €920,127 | €13,952,298 | — |
| 2018 | Rohergebnis€8.5M2 | €1,890,383 | €13,200,247 | — |
| 2017 | Rohergebnis€7.9M2 | €1,570,312 | €13,258,338 | — |
| 2016 | €11,727,907 | €1,234,955 | €10,806,333 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 47940 (as of 2 November 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €2,463,440 | 99.3% |
| Depreciation | €16,302 | 0.7% |
